Type of non Hodgkin's lymphoma-Other-Small cell lymphocytic lymphoma Posts on Medivizor
Navigation Menu

Type of non Hodgkin’s lymphoma-Other-Small cell lymphocytic lymphoma Posts on Medivizor

Comparing targeted therapy and chemoimmunotherapy as a frontline treatment for chronic lymphocytic leukemia and small lymphocytic lymphoma

Comparing targeted therapy and chemoimmunotherapy as a frontline treatment for chronic lymphocytic leukemia and small lymphocytic lymphoma

Posted by on Aug 1, 2021 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This review aimed to compare the benefits and risks associated with targeted therapy (TT) and chemoimmunotherapy (CIT) as frontline treatments for chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).  Some background The number of treatment options for CLL and SLL has increased in the last few years. For a long...

Read More

Comparing targeted therapy and chemoimmunotherapy as a frontline treatment for chronic lymphocytic leukemia and small lymphocytic lymphoma

Comparing targeted therapy and chemoimmunotherapy as a frontline treatment for chronic lymphocytic leukemia and small lymphocytic lymphoma

Posted by on Aug 1, 2021 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This review aimed to compare the benefits and risks associated with targeted therapy (TT) and chemoimmunotherapy (CIT) as frontline treatments for chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).  Some background The number of treatment options for CLL and SLL has increased in the last few years. For a long...

Read More

Copanlisib plus rituximab improves survival in patients with relapsed painless non-Hodgkin lymphoma.

Copanlisib plus rituximab improves survival in patients with relapsed painless non-Hodgkin lymphoma.

Posted by on May 22, 2021 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study reported the effectiveness and safety outcomes of copanlisib (Aliqopa) and rituximab (Rituxan) combination for the treatment of patients with relapsed indolent (painless) non-Hodgkin lymphoma (NHL). The data showed that this combination improved the outcomes of these patients with manageable side effects. Some background...

Read More

Comparing rituximab to newer anti-CD20 monoclonal antibodies for induction therapy of CD20+ B-cell non-Hodgkin lymphomas

Comparing rituximab to newer anti-CD20 monoclonal antibodies for induction therapy of CD20+ B-cell non-Hodgkin lymphomas

Posted by on Feb 28, 2021 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study aimed to compare standard therapy Rituximab (Rituxan) to newer anti-CD20 monoclonal antibodies (mAbs) such as obinutuzumab (Gazyva), ofatumumab (Arzerra), 131I-tositumomab (Bexxar), and 90Y-ibritumomab tiuxetan (Zevalin) for the treatment of patients with B-cell non-Hodgkin lymphomas (B-NHL). The authors concluded...

Read More

Outcomes of lisocabtagene maraleucel in patients with relapsed or refractory large B-cell lymphomas

Outcomes of lisocabtagene maraleucel in patients with relapsed or refractory large B-cell lymphomas

Posted by on Sep 13, 2020 in Non-Hodgkin lymphoma | 0 comments

In a nutshell The study evaluated the effectiveness and safety of lisocabtagene maraleucel (Liso-cel) in treating patients with relapsed or refractory (r/r) large B-cell lymphomas (LBCL). The authors found that liso-cel achieved fast and lasting remission with fewer toxicities in such patients. Some background Patients with r/r-LBCL experience...

Read More

How effective and safe is biological therapy rituximab for children with non-Hodgkin lymphoma?

How effective and safe is biological therapy rituximab for children with non-Hodgkin lymphoma?

Posted by on Jun 21, 2020 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study examined if adding biological therapy rituximab (Rituxan) to chemotherapy improved treatment results for children with non-Hodgkin lymphoma. The results showed that rituximab improved patients’ chances of survival but also caused more side effects. Some background Treatment results for children with NHL have...

Read More

Is R-CVP safer and more effective than R-CHOP for patients with painless NHL?

Posted by on Feb 5, 2020 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the safety and effectiveness of two different chemotherapy regimens for patients with indolent (painless) non-Hodgkin’s lymphoma (NHL). This study found that the R-CVP regimen was similarly effective and had fewer side effects compared to R-CHOP for these patients. Some background Chemoimmunotherapy is the...

Read More

Surviving cancer – is there a greater risk of cardiovascular disease long-term?

Posted by on Sep 16, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study investigated if there is a higher risk of cardiovascular disease (CVD) in cancer survivors.  They found that cancer survivors have a higher risk of CVD. Some background Improved cancer detection and treatment has increased the rates of survival. The number of cancer survivors living for more than 10 years is growing. Some...

Read More

Combination of ublituximab, umbralisib and ibrutinib for patients with leukemia and lymphoma

Posted by on May 9, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study aimed to investigate the safety and effectiveness of ublituximab, umbralisib and ibrutinib combination in patients with non-Hodgkin lymphoma (NHL). This study concluded that this combination appears safe and effective for these patients.  Some background Patients with NHL are often treated with targeted therapies....

Read More

Does G-B treatment improve survival outcomes for patients with refractory follicular lymphoma?

Posted by on May 12, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study investigated the outcomes of patients with indolent (painless) refractory (does not respond to treatment) non-Hodgkin’s lymphoma (NHL) after G-B (obinutuzumab, bendamustine) treatment. This study concluded that G-B improved survival outcomes for NHL patients with similar side effects as bendamustine (Treanda)...

Read More

What are the long-term outcomes following bendamustine treatment?

Posted by on Mar 12, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study examined the long-term safety and effectiveness of bendamustine (Treanda) in lymphoma and leukemia. This study concluded that bendamustine is a safe and effective therapy for these patients. Some background Bendamustine has been shown to have high effectiveness and few side effects for a wide range of lymphomas. This drug is...

Read More